AMRI second quarter total revenue increases 9 percent to $53.
Our practice will be revisited as we enter 2012. We estimate gross margins will be consistent with prior year while research and advancement expense is likely to decrease between 10-15 percent and offering, general and administrative expenditure should be flat to down ~5 percent with the prior year. Recent Highlights Latest noteworthy announcements or milestones at AMRI include the following: The successful completion of a Stage I clinical research on novel MCH1 receptor antagonist, ALB-127158. The results indicate that ALB-127158 is normally well tolerated at the dosages tested and displays preliminary proof efficacy.We have become proud to have this most modern technology which is the basis for our whole monitoring products and honored by its acknowledgement by Frost and Sullivan. Because the successful intro of the CIPAM we’ve already started the development of our next era – the CIPAM Pro which is based on Motorola’s most recent advanced OMAP 3 technology. This will be presented to the market, during 2010, with new together, state of the artwork products, and expand our product variety therefore. I have without doubt that the high quality of our existing products and the brand new products being released, will assure Mennen Medical’s continuation as a leader of new systems and innovations.